PATENT

ATTORNEY DOCKET NO.: 056291-0006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent No. 5,770,599)	
Issued: June 23, 1998)	
Patentees: Keith Hopkinson GIBSON)	
Assignee: Zeneca Limited)	
FOR: QUINAZOLINE DERIVATIVES)	
	j)	
)	
Commissioner for Patents	•	Date: July 2, 2003
U.S. Patent and Trademark Office		• ,
2011 South Clark Place		
Customer Window, Mail Stop		
Crystal Plaza Two, Lobby, Room 1B03		
Arlington, VA 22202		

SUBMISSION OF REVOCATION OF ORIGINAL POWER OF ATTORNEY AND GRANT OF NEW POWER OF ATTORNEY

Sir:

Attached hereto is a REVOCATION OF ORIGINAL POWER OF ATTORNEY

AND GRANT OF NEW POWER OF ATTORNEY (with attachments) revoking all previous

powers of attorney and granting power of attorney to Morgan Lewis & Bockius LLP.

Please address further correspondence to the undersigned (**Donald J. Bird**) at the following address:

CUSTOMER NO. 009629 MORGAN, LEWIS & BOCKIUS LLP 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 (202) 739-3000

ATTORNEY DOCKET NO.: 056291-0006

U.S Patent No. 5,770,599

Page 2

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 50-0310.

By:

Respectfully Submitted,

Morgan Lewis & Bockins LLP

Date: July 2, 2003

Morgan Lewis & Bockius LLP

Customer No. 009629

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004 Tel. No.: 202-739-3000

DJB:mk

Donald J. Bird

Registration No. 25,323 Tel. No.: (202) 739-5320

Fax No.: (202) 739-3001

PATENT

ATTORNEY DOCKET NO.: 056291-0006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent No. 5,770,599)
Issued: June 23, 1998)
Patentees: Keith Hopkins GIBSON)
Assignee: Zeneca Limited)
FOR: QUINAZOLINE DERIVATIVES)
)
)
Commissioner for Patents	
U.S. Patent and Trademark Office	
2011 South Clark Place	
Customer Window, Mail Stop	
Crystal Plaza Two, Lobby, Room 1B03	
Arlington, VA 22202	

REVOCATION OF ORIGINAL POWER OF ATTORNEY AND GRANT OF NEW POWER OF ATTORNEY

Sir:

AstraZeneca UK Limited, as assignee of U.S. Patent No. 5,770,599 issued June 23, 1998, by virtue of an assignment from the inventors thereof to ZENECA LIMITED recorded April 26, 1996 at Reel 7973, Frame 0532; by change of name of ZENECA LIMITED to Syngenta Limited, a copy of the change of name certificate being attached hereto; and by Assignment from Syngenta Limited to AstraZeneca UK Limited, a copy of that assignment being attached hereto, hereby revokes all previous Powers of Attorney in U.S. Patent No. 5,770,599 and any application leading thereto, and hereby grants in respect of said Patent, Power of Attorney to the registered practitioners of Morgan, Lewis & Bockius LLP included in the Customer Number provided below to transact all business in the Patent and Trademark Office connected therewith.

Assignee further directs that all correspondence be addressed to the Customer Number given below:

Customer Number: 009629

Please direct all telephone inquiries to:

Donald J. Bird Morgan, Lewis & Bockius LLP 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 Telephone: (202) 739-5320 Facsimile: (202) 739-3001

Certificate under 37 C.F.R. 3.73(b)

AstraZeneca UK Limited, 15 Stanhope Gate, London, England W1Y 6LN, certifies that it is the assignee of the entire right, title and interest in the Patent identified above. The assignment from the inventor(s) of such Patent and/or the application(s) from which such Patent issued, as well as subsequent assignments and change of name certificate providing an unbroken chain of title in said Patent to AstraZeneca UK Limited, have been recorded as indicated above, or copies are attached hereto and have been provided to the above-identified counsel with instructions and authorization to file same for recordation at the time this Power is filed. To the best of the undersigned's knowledge and belief, title is in the assignee identified above. The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001. Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

AstraZeneca UK, Limited

Name: JOHN R. MACK

Title: GLOBAL LICABING MANAGER

Date: 20 June 2003